| Progress and prospects: immune responses to viral vectors S Nayak, RW Herzog Gene therapy 17 (3), 295-304, 2010 | 756 | 2010 |
| Induction and role of regulatory CD4+ CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer O Cao, E Dobrzynski, L Wang, S Nayak, B Mingle, C Terhorst, RW Herzog Blood 110 (4), 1132-1140, 2007 | 251 | 2007 |
| Glucose oxidation modulates anoikis and tumor metastasis S Kamarajugadda, L Stemboroski, Q Cai, NE Simpson, S Nayak, M Tan, ... Molecular and cellular biology 32 (10), 1893-1907, 2012 | 246 | 2012 |
| Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis S Kamarajugadda, Q Cai, H Chen, S Nayak, J Zhu, M He, Y Jin, Y Zhang, ... Cell death & disease 4 (2), e504, 2013 | 148 | 2013 |
| B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study M Corti, ME Elder, DJ Falk, L Lawson, BK Smith, S Nayak, TJ Conlon, ... Molecular Therapy—Methods & Clinical Development 1, 2014 | 123 | 2014 |
| GITR engagement preferentially enhances proliferation of functionally competent CD4+ CD25+ FoxP3+ regulatory T cells G Liao, S Nayak, JR Regueiro, SB Berger, C Detre, X Romero, ... International immunology 22 (4), 259-270, 2010 | 122 | 2010 |
| Pompe disease gene therapy BJ Byrne, DJ Falk, CA Pacak, S Nayak, RW Herzog, ME Elder, SW Collins, ... Human molecular genetics, ddr174, 2011 | 121 | 2011 |
| Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies DM Markusic, BE Hoffman, GQ Perrin, S Nayak, X Wang, PA LoDuca, ... EMBO molecular medicine 5 (11), 1698-1709, 2013 | 115 | 2013 |
| Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B O Cao, BE Hoffman, B Moghimi, S Nayak, M Cooper, S Zhou, HCJ Ertl, ... Molecular Therapy 17 (10), 1733-1742, 2009 | 111 | 2009 |
| Induction of tolerance to factor VIII by transient co‐administration with rapamycin B Moghimi, BK Sack, S Nayak, DM Markusic, CS Mah, RW Herzog Journal of Thrombosis and Haemostasis 9 (8), 1524-1533, 2011 | 107 | 2011 |
| Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer M Cooper, S Nayak, BE Hoffman, C Terhorst, O Cao, RW Herzog Human gene therapy 20 (7), 767-776, 2009 | 95 | 2009 |
| Sustained Correction of Motoneuron Histopathology Following Intramuscular Delivery of AAV in Pompe Mice MK ElMallah, DJ Falk, S Nayak, RA Federico, MS Sandhu, A Poirier, ... Molecular Therapy 22 (4), 702-712, 2014 | 93 | 2014 |
| B-Cell Depletion and Immunomodulation before Initiation of Enzyme Replacement Therapy Blocks the Immune Response to Acid Alpha-Glucosidase in Infantile-Onset Pompe Disease ME Elder, S Nayak, SW Collins, LA Lawson, JS Kelley, RW Herzog, ... The Journal of pediatrics 163 (3), 847-854. e1, 2013 | 80 | 2013 |
| Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell–dependent induction of CD4+ CD25+ FoxP3+ Treg M Biswas, D Sarkar, SRP Kumar, S Nayak, GL Rogers, DM Markusic, ... Blood 125 (19), 2937-2947, 2015 | 76 | 2015 |
| Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer—Implications for Antigen Presentation and Immunotoxicity AT Martino, S Nayak, BE Hoffman, M Cooper, G Liao, DM Markusic, ... PloS one 4 (8), e6376, 2009 | 70 | 2009 |
| Prophylactic immune tolerance induced by changing the ratio of antigen‐specific effector to regulatory T cells S Nayak, O Cao, BE Hoffman, M Cooper, S Zhou, MA Atkinson, ... Journal of Thrombosis and Haemostasis 7 (9), 1523-1532, 2009 | 67 | 2009 |
| Co-Packaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease PA Doerfler, AG Todd, N Clement, D Falk, S Nayak, R Herzog, BJ Byrne Human gene therapy, 2015 | 59 | 2015 |
| Prevention and reversal of antibody responses against factor IX in gene therapy for hemophilia B S Nayak, D Sarkar, GQ Perrin, B Moghimi, BE Hoffman, S Zhou, BJ Byrne, ... Frontiers in microbiology 2, 2011 | 53 | 2011 |
| Targeted approaches to induce immune tolerance for Pompe disease therapy PA Doerfler, S Nayak, M Corti, L Morel, RW Herzog, BJ Byrne Molecular therapy. Methods & clinical development 3, 15053, 2016 | 48 | 2016 |
| Immune Responses and Hypercoagulation in ERT for Pompe Disease Are Mutation and rhGAA Dose Dependent S Nayak, PA Doerfler, SL Porvasnik, DD Cloutier, R Khanna, ... PloS one 9 (6), e98336, 2014 | 28 | 2014 |
Barry J. ByrneUniversity of Florida在 ufl.edu 的电子邮件经过验证
